文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

可生物降解球囊直肠间隔物用于前列腺放疗的前瞻性随机对照关键性试验

Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-07-19

这项前瞻性随机对照关键性试验在16个中心纳入222例T1-T3期无磁共振证据提示后侧前列腺外侵犯的前列腺癌患者,按2:1随机分组接受经会阴经直肠超声引导下基准标记放置±可生物降解球囊直肠间隔物,随后行调强放疗。试验达到主要疗效终点:球囊组97.9%(139/142)的患者直肠V70降低>25%(P<.001),平均V70由植入前7.0%降至植入后1.1%;主要安全性终点亦达到,球囊组≥1级不良事件发生率18% vs 对照组23%(非劣效P<.001)。

要点

  • 球囊组97.9%(139/142)患者直肠V70降低>25%,达到主要疗效终点(P<.001)。
  • 平均V70由植入前7.0%降至植入后1.1%,平均直肠周围间距19±3.7 mm并在放疗期间维持(18±3.9 mm)。
  • 球囊组≥1级不良事件18% vs 对照组23%(非劣效P<.001),达到主要安全性终点。

核心结论

  • 可生物降解直肠间隔球囊能有效显著降低直肠受照剂量,并与直肠及植入相关累积不良事件减少相关。
  • 6个月时均观察到球囊吸收。

研究设计与样本

  • 前瞻性随机对照关键性试验,共纳入222例受试者,在16个中心入组。
  • 所有患者为T1-T3期前列腺癌,且无磁共振成像证据提示后侧前列腺外侵犯。
  • 随机化比例为2:1(球囊组:对照组),受试者设盲。
  • 患者接受经会阴经直肠超声轴位及矢状位引导下基准标记放置±球囊,随后行调强放疗(81 Gy,每次1.8 Gy,或生物等效大分割剂量)。
  • 疗效比较由中心核心实验室在植入前和植入后计算机断层扫描上生成计划。

主要发现

  • 主要疗效终点达到:球囊组97.9%(139/142)的患者直肠V70降低>25%(P<.001)。
  • 平均V70为植入前7.0% vs 植入后1.1%。
  • 主要安全性终点达到:球囊组≥1级事件发生率18% vs 对照组23%(非劣效P<.001)。
  • 预设次要终点≥2级事件发生率在球囊组趋势更低(4.3% vs 6.5%,P=.527)。
  • 平均直肠周围间距为19±3.7 mm,并在放疗期间维持(18±3.9 mm);6个月计算机断层扫描显示98.5%(133/135)的受试者球囊吸收。

关键数值与推荐

  • 主要疗效终点:球囊组97.9%(139/142)患者直肠V70降低>25%(P<.001)。
  • 主要安全性终点:球囊组≥1级事件18% vs 对照组23%(非劣效P<.001)。
  • 预设次要终点:≥2级事件球囊组4.3% vs 对照组6.5%(P=.527)。
  • 平均直肠周围间距19±3.7 mm,放疗期间18±3.9 mm。
  • 6个月计算机断层扫描球囊吸收率98.5%(133/135)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVES: Rectal spacers have been shown to reduce rectal side effects in patients receiving prostate radiation. However, concerns remain regarding precise and reproducible gel injection. We evaluated efficacy and safety of a novel rectoprostatic spacer balloon that allows potential for controlled, adaptable deployment. This study tested co-primary hypotheses: (1) balloon spacer would result in ≥25% reduction of rectal V70 in >75% of subjects and (2) implantation procedure-related and rectal ≥grade 1 adverse events within 6 months (duration ≥2 days, Common Terminology Criteria for Adverse Events 4.0) would be noninferior in balloon versus control subjects. METHODS AND MATERIALS: A total of 222 subjects were enrolled at 16 centers. All patients had T1-T3 prostate cancer without magnetic resonance imaging evidence of posterior extraprostatic invasion. Randomization was 2:1 (balloon: control) and subject-blinded. Patients underwent transperineal transrectal ultrasound axial and sagittal-guided fiducial placement ± balloon, followed by Intensity-Modulated Radiation Therapy (81 Gy in 1.8 Gy fractions or biologically equivalent hypofractionated dose). For efficacy comparisons, plans were generated by a central core lab on pre- and postimplant computed tomography scans. RESULTS: The primary efficacy endpoint was met, with 97.9% of balloon subjects (139/142) having rectal V70 reduction >25% (P < .001). Mean V70 was 7.0 % pre- versus 1.1% postimplant. The primary safety endpoint was met with balloon subjects experiencing fewer ≥grade 1 events, 18% versus 23% (P < .001 for noninferiority). On predefined secondary endpoint of ≥grade 2 events, rates trended lower in balloon subjects (4.3% vs 6.5%, P = .527). Mean perirectal spacing was 19 ± 3.7 mm and maintained through radiation treatment (18 ± 3.9 mm). Balloon resorption was observed on 6-month computed tomography in 98.5% (133/135) of subjects. The Expanded Prostate Cancer Index quality of life instrument was collected throughout study, and did not differ statistically between the study arms. CONCLUSIONS: Biodegradable rectal spacer balloon was effective in significantly reducing dose to rectum, and associated with decreased cumulative rectal plus implantation-related adverse events. Balloon resorption was consistently observed by 6 months.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Song D, Dabkowski M, Costa P, et al. Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024. PMID: 39032758. doi:10.1016/j.ijrobp.2024.07.2145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。